Matthias Schroff (Vaximm AG)

Schroff, Matthias (Vaximm 201609– CEO before Mologen CEO)

	Organisation	Vaximm AG
	Group	Vaximm (Group)
	Former/major organisation	Mologen AG
	Group	Mologen (Group)
	Product	therapeutic vaccine
	Product 2	cancer immunotherapy (immuno-oncology, I-O)

Record changed: 2018-02-20

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Matthias Schroff

[1] Vaximm AG. (5/18/17). "Press Release: VAXIMM Announces Data from Phase I Trial in Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2017 Annual Meeting". Basel & Mannheim....
[2] Vaximm AG. (5/9/17). "Press Release: Vaximm Announces Collaboration with Merck KGaA, Darmstadt, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies". Basel & Mannheim....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]